[12] Patent
[11] Patent No.:GC0007522  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125689
Date of the Decision to Grant the Patent:05/Apr/2018

[21] Application No.:GC 2012-20886

[22] Filing Date:27/3/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
5/4/2011
11161111.7

[72] Inventors:1- Jan-Georg PETERS،2- Hans-Christian MILITZER،3- Hartwig MÜLLER

[73] Owner: Bayer Intellectual Property GmbH, Alfred-Nobel-Strasse 10, 40789, Monheim am Rhein, Germany

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: [C07D487/04;A61K31/519;A61P35/00] (2006.01)

[56] Cited Documents:

-WO 2008070150 A1 (BAYER PHARMACEUTICALS CORP [US]; HENTEMANN MARTIN [US]; WOOD JILL [US]) 12 June 2008
-EP 2168582 A1 (BAYER SCHERING PHARMA AG [DE]) 31 March 2010
-WO 2010034414 A1 (BAYER SCHERING PHARMA AG [DE]; LIU NINGSHU [DE]) 01 April 2010
 
Examiner: PH. Sultana K. AlOudah

[54] SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS
[57] Abstract: The present invention relates :‎‎- to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-‎‎[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of ‎formula (II) :‎ ‎(II),‎or a tautomer, solvate or hydrate thereof ;‎‎- to methods of preparing said dihydrochloride salt ;‎‎- to said dihydrochloride salt for the treatment and/or prophylaxis of a ‎disease;‎‎- to the use of said dihydrochloride salt for the preparation of a medicament ‎for the treatment and/or prophylaxis of a disease, in particular of a hyper-‎proliferative and/or angiogenesis disorder, more particularly for the ‎treatment or prophylaxis of a cancer, particularly lung cancer, in particular ‎non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic ‎cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or ‎breast cancer ;‎‎- to a pharmaceutical composition comprising said dihydrochloride salt ; and‎‎- to a pharmaceutical combination comprising said dihydrochloride salt in ‎combination with one or more further pharmaceutical agents.
No. of claims: 16     No. of figures: 7


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.